Journal
PHARMACOGENOMICS JOURNAL
Volume 14, Issue 4, Pages 395-399Publisher
SPRINGERNATURE
DOI: 10.1038/tpj.2013.51
Keywords
antidepressant; copy number variants; major depressive disorder; psychiatry; treatment response; 15q13.3
Categories
Funding
- Wellcome Trust [086635]
- Innovative Medicine Initiative Joint Undertaking (IMI-JU) [115008]
- European Federation of Pharmaceutical Industries and Associations (EFPIA)
- European Union
- European Commission, EC [LSHB-CT-2003-503428]
- UK National Institute for Health Research of the Department of Health
- UK Medical Research Council (MRC, UK)
- GlaxoSmithKline [G0701420]
- Medical Research Council (MRC, UK)
- Mental Health Research Network
- Canada Research Chair program
- Wyeth-Lederle
- Bristol-Myers-Squibb
- Sanofi Aventis
- Lundbeck Foundation [R155-2014-1724] Funding Source: researchfish
- Medical Research Council [G0200243, MR/L010305/1, G0800509, MC_UU_12013/4, G0701748, G0701420] Funding Source: researchfish
- MRC [G0800509, G0701420, G0701748, G0200243, MC_UU_12013/4] Funding Source: UKRI
Ask authors/readers for more resources
It would be beneficial to find genetic predictors of antidepressant response to help personalise treatment of major depressive disorder (MDD). Rare copy number variants (CNVs) have been implicated in several psychiatric disorders, including MDD, but their role in antidepressant response has yet to be investigated. CNV data were available for 1565 individuals with MDD from the NEWMEDS (Novel Methods leading to New Medications in Depression and Schizophrenia) consortium with prospective data on treatment outcome with either a serotonergic or noradrenergic antidepressant. No association was seen between the presence of CNV (rare or common), the overall number of CNVs or genomic CNV 'burden' and antidepressant response. Specific CNVs were nominally associated with antidepressant response, including 15q13.3 duplications and exonic NRXN1 deletions. These were associated with poor response to antidepressants. Overall burden of CNVs is unlikely to contribute to personalising antidepressant treatment. Specific CNVs associated with antidepressant treatment require replication and further study to confirm their role in the therapeutic action of antidepressant.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available